Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Immunome (IMNM) EBITDA Margin (2023 - 2025)

Immunome (IMNM) has disclosed EBITDA Margin for 3 consecutive years, with 1157.61% as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, EBITDA Margin rose 53482.0% year-over-year to 1157.61%, compared with a TTM value of 3228.83% through Dec 2025, up 15354.0%, and an annual FY2025 reading of 3228.83%, up 15354.0% over the prior year.
  • EBITDA Margin was 1157.61% for Q2 2025 at Immunome, up from 1525.5% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 129.96% in Q3 2023 and bottomed at 12857.05% in Q1 2024.
  • Average EBITDA Margin over 3 years is 2492.75%, with a median of 1608.96% recorded in 2025.
  • The sharpest move saw EBITDA Margin crashed -1266792bps in 2024, then soared 1133155bps in 2025.
  • Year by year, EBITDA Margin stood at 2473.94% in 2023, then dropped by -22bps to 3030.31% in 2024, then surged by 62bps to 1157.61% in 2025.
  • Business Quant data shows EBITDA Margin for IMNM at 1157.61% in Q2 2025, 1525.5% in Q1 2025, and 3030.31% in Q4 2024.